SCHEMBL1922564

SCHEMBL1922564

Cc1nn2c(-c3ccc(Cl)cc3Cl)c(C)oc2c1[N+](=O)[O-]

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 2/20 0.41
HPGD P15428 2/20 0.39
TP53 P04637 1/20 0.39
DPP4 P27487 3/20 0.38
TNF P01375 1/20 0.37
APEX1 P27695 1/20 0.37
KMT2A Q03164 3/20 0.36
CRHR1 P34998 3/20 0.36
MEN1 O00255 1/20 0.36
MAPT P10636 2/20 0.36
DPP8 Q6V1X1 1/20 0.36
POLB P06746 1/20 0.36
ALDH1A1 P00352 2/20 0.35
LMNA P02545 1/20 0.35
TSHR P16473 1/20 0.35
MAPK1 P28482 1/20 0.35
USP2 O75604 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2258180 0.87 HSD11B1 (0.39) HSD11B1HPGDTP53DPP4TNF
SCHEMBL12360976 0.87 HSD11B1 (0.39) HSD11B1HPGDTP53DPP4TNF
SCHEMBL2256347 0.85 CRHR1 (0.38) HSD11B1HPGDTP53DPP4APEX1
SCHEMBL1922300 0.79 DPP4 (0.42) HSD11B1HPGDDPP4KMT2ACRHR1
SCHEMBL1922992 0.79 DPP4 (0.42) HSD11B1HPGDDPP4KMT2ACRHR1
SCHEMBL1922301 0.79 DPP4 (0.44) HSD11B1HPGDDPP4KMT2ACRHR1
SCHEMBL1922267 0.79 DPP4 (0.40) HSD11B1HPGDDPP4KMT2ACRHR1
SCHEMBL1922297 0.78 LMNA (0.48) HPGDDPP4KMT2ACRHR1MAPT
SCHEMBL5847576 0.78 HSD11B1 (0.42) HSD11B1HPGDTP53DPP4TNF
SCHEMBL1922979 0.78 LMNA (0.40) HSD11B1HPGDDPP4KMT2ACRHR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7994203-B2 Organic compounds NOVARTIS AG (CH) 2011-08-09 US disclosed
EP-2328902-A1 PYRAZOLO [5,1-B]OXAZOLE DERIVATIVES AS CRF1 ANTAGONISTS Novartis AG (CH) 2011-06-08 EP disclosed
WO-2010015628-A1 PYRAZOLO [5,1-B] OXAZOLE DERIVATIVES AS CRF1 ANTAGONISTS NOVARTIS AG (CH) 2010-02-11 WO disclosed
US-20100035874-A1 Organic compounds NOVARTIS AG (CH) 2010-02-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100035874-A1 Organic compounds CRH, CRHR1, CRHR2 HSD11B1 229/4885HPGD 1748/4885TP53 4211/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.